Although the technology is still in its infancy, several devices have been tested in clinical trials and the initial results have been very promising. This review will discuss the emerging need for BRS, the theoretical advantages of this new technology over current generation metallic DES and review the status of the currently available BRS. In addition, we will discuss the ideal duration of bioresorption, the proven and potential clinical benefits and future
perspectives of this rapidly progressing technology. (Circ J 2011; 75: 509-520)”
“Background: AS1842856 datasheet Asthma is a leading cause of pediatric hospitalizations across the country, yet no clinical instrument exists that incorporates the child’s perception of dyspnea in determining discharge readiness.\n\nObjective: We sought to develop the Pediatric
Dyspnea Scale (PDS) to support discharge decision making in hospitalized asthmatic patients and to compare the performance of the PDS with traditional markers of asthma control in predicting outcomes after discharge.\n\nMethods: Asthmatic children aged 6 to 18 years hospitalized for an exacerbation were included in the study. The PDS score, demographics, asthma severity, spirometric results, peak expiratory How rate, and fraction of exhaled nitric oxide were assessed at the time of discharge. A telephone call 14 days after discharge determined relapse, EGFR inhibitor activity limitation, asthma control, and asthma-related quality-of-life outcomes.\n\nResults: Eighty-nine patients were enrolled, of whom 70 completed the telephone follow-up. Eight patients had a relapse, and 29 complained of limited activity. A PDS score of greater than 2 on the 7-point scale was a significant predictor
of these poor outcomes, with each additional point of the PDS doubling the risk. A higher score on BEZ235 inhibitor the PDS also correlated with worse asthma control and poor asthma-specific quality of life. The PDS performed better than FEV(1), peak expiratory flow rate, or fraction of exhaled nitric oxide in predicting the outcomes of interest.\n\nConclusion: The PDS, which is easy to use in children as young as 6 years of age, might be able to predict adverse outcomes after hospitalization for an asthma exacerbation and should be used as a tool to help guide inpatient discharge decisions. (J Allergy Clin Immunol 2009;123:660-4.)”
“The eigenvalues of a population projection matrix – except for the Lotka coefficient – are uniquely determined by the reproductive values and the survival. This relation (proposed earlier, but not really well known in western literature) follows from another useful relation between fertility, reproductive values, survival, and Lotka’s coefficient. These results are applied to provide demographic interpretations to the intrinsically dynamic and metastable population models by Schoen and co-workers. (C) 2010 Elsevier Inc. All rights reserved.